Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.02 – $0.02
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $333.0K | $356.0K | $362.0K | $844.0K | $1.1M | $1.6M | $931.0K | $683.3K |
| Cost of revenue | −$25.1M | −$26.7M | −$40.0M | −$15.0M | $4.2M | $6.7M | $9.7M | $136.0K |
| Gross profit | $25.4M | $27.1M | $40.4M | $15.8M | −$3.1M | −$5.1M | $931.0K | $549.0K |
| Gross margin | 7623.1% | 7604.5% | 11155.2% | 1873.6% | -267.8% | -324.3% | 100.0% | 80.3% |
| R&D | $2.9M | $3.7M | $5.9M | $4.7M | $4.6M | $2.8M | $2.6M | $0 |
| Operating income | −$87.7M | −$114.2M | −$134.3M | −$166.6M | −$191.2M | −$296.5M | −$109.4M | −$80.5M |
| EBITDA | −$85.5M | −$104.8M | −$134.9M | −$135.5M | −$141.6M | −$148.5M | −$61.3M | −$77.0M |
| Net income | −$86.5M | −$114.5M | −$146.0M | −$156.0M | −$168.1M | −$309.4M | −$76.5M | −$145.5M |
| Net margin | -25987.7% | -32168.8% | -40340.6% | -18479.4% | -14680.5% | -19646.9% | -8221.4% | -21301.5% |
| EPS (diluted) | -4.33 | -5.43 | -6.35 | -6.40 | -6.89 | -7.95 | -0.93 | -0.42 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-0.10 | $-0.10–$-0.10 | 1 |
| 2027 | $17M | $-0.04 | $-0.04–$-0.04 | 1 |
| 2028 | $55M | $-0.02 | $-0.02–$-0.02 | 1 |
| 2029 | $109M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
IMMUNOVIA AB
No one on the platform currently holds IMMVF.
No tracked institution reports a position in IMMVF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2018-05-10 | 1-for-3.2reverse |
No one on the platform has traded IMMVF yet.
| $101821 |
| — |
| OPGNOpGen, Inc. | $23.91 | +64.36% | $243M | — |
| PPCBPropanc Biopharma, Inc. | $1.45 | -3.33% | $1M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.